Main Factors Driving Acyclovir Resistance
Acyclovir resistance in herpes simplex virus (HSV) or varicella-zoster virus (VZV) develops primarily through viral mutations that impair the drug's mechanism. Acyclovir requires activation by viral thymidine kinase (TK) to form acyclovir triphosphate, which inhibits viral DNA polymerase. Key mutations include:
- Thymidine kinase deficiencies: Loss or alteration of TK gene function prevents drug phosphorylation. This accounts for ~95% of HSV cases and ~75-90% of VZV cases in immunocompromised patients.[1][2]
- DNA polymerase mutations: Changes in the viral polymerase reduce binding affinity for acyclovir triphosphate, seen in ~5% of HSV cases.[1]
- Combined defects: Rare overlaps of TK and polymerase mutations accelerate resistance.[2]
These genetic changes arise spontaneously at low rates (10^-5 to 10^-8 per replication cycle) but become clinically relevant under selection pressure.[3]
Why Does Prolonged or Frequent Use Increase Risk?
High exposure selects for resistant mutants. Common triggers:
- Repeated or prolonged acyclovir dosing in chronic infections allows replication of mutants.
- Prophylactic therapy in transplant or HIV patients amplifies risk, with resistance rates up to 30-40% after 1-2 years.[1][4]
- Incomplete treatment courses enable partial viral suppression, favoring resistant subpopulations.[3]
Who Is Most at Risk?
Immunocompromised patients face the highest incidence:
- HIV/AIDS: Up to 5-10% resistance in advanced cases.[1]
- Transplant recipients or chemotherapy patients: 4-7% for HSV, higher for VZV.[2][4]
- Neonates or severe primary infections: Rare but aggressive due to immature immunity.[3]
Immunocompetent individuals rarely develop resistance (<1%), typically only after decades of episodic use.[1]
How Does Virus Type Affect Resistance Patterns?
- HSV-1 and HSV-2: TK mutations dominate; HSV-2 shows slightly higher baseline rates in genital infections.[1][3]
- VZV: More polymerase mutations; resistance emerges faster in zoster prophylaxis.[2]
Cross-resistance occurs within nucleoside analogs (e.g., valacyclovir, famciclovir) but not foscarnet.[4]
What Treatment Practices Contribute?
- Monotherapy overuse: Exclusive reliance on acyclovir without alternation fosters selection.
- Subtherapeutic dosing: Low serum levels from poor absorption or non-compliance allow mutant outgrowth.[3]
- Nosocomial spread: Resistant strains transmit in hospitals, especially among immunocompromised clusters.[4]
Can Resistance Reverse or Be Prevented?
Resistance is stable but viral fitness costs (e.g., reduced replication) limit spread in healthy hosts.[3] Prevention strategies:
- Limit prophylaxis duration.
- Use higher doses (e.g., IV acyclovir 10 mg/kg).
- Switch to foscarnet or cidofovir for confirmed cases; combinations under study.[2][4]
No vaccines yet target resistant strains specifically.
Emerging Concerns and Alternatives
Rising rates in immunocompromised populations prompt surveillance. Alternatives like letermovir (for CMV cross-insights) or novel helicase-primase inhibitors show promise against resistant HSV.[3][4]
[1]: CDC - Antiviral Resistance in HSV/VZV
[2]: Journal of Infectious Diseases - VZV Resistance Mechanisms
[3]: Clinical Infectious Diseases - HSV Resistance Review
[4]: New England Journal of Medicine - Management of Resistant Herpesviruses